Pharmaceutical companies are attempting to maximize value from all angles, including internal investment in R&D and externalization via deal-making. The growth in these two models has had an impact on both revenue derived from internally developed products, as well as externalized drugs. This report is a written adaptation of a webinar presented in May 2017 by Datamonitor Healthcare titled “From R&D Investment to Externalization: Where is the Pharma Industry Maximizing Value?”.

This Datamonitor Healthcare report contains a Strategy module.